Table 2.
| Immunologic variable | No Treatment | Treatment | ||||
|---|---|---|---|---|---|---|
| N | Median (IQR) | R,% | N | Median (IQR) | R,% | |
| Cytokine | ||||||
| IL-10 | ||||||
| Medium | 102 | 0 (0-0) | 20 | 95 | 0 (0-0) | 13 |
| SEB | 102 | 131 (86-217) | 92 | 95 | 116 (55-212) | 97 |
| Ascaris | 102 | 0 (0-8)* | 27* | 95 | 0 (0-0) | 9 |
| PPD | 102 | 0 (0-18)* | 34 | 95 | 0 (0-0) | 20 |
| LPS | 102 | 1,503 (1,1016-2,035) | 100 | 95 | 1,284 (817-1,949) | 100 |
| Cockroach | 102 | 14 (0-50) | 64 | 95 | 22 (0-122) | 61 |
| HDM | 102 | 0 (0-221) | 50 | 95 | 0 (0-278) | 43 |
| IFN-□ | ||||||
| Medium | 107 | 0 (0-0) | 15 | 107 | 0 (0-0) | 11 |
| SEB | 107 | 9,961 (9,160-9,961) | 100 | 107 | 9,961 (9,257-9,961) | 100 |
| Ascaris | 107 | 0 (0-2) | 28 | 107 | 0 (0-28) | 32 |
| PPD | 107 | 72 (4-389) | 77 | 107 | 107 (3-521) | 79 |
| LPS | 107 | 68 (0-407) | 74 | 107 | 71 (0-402) | 69 |
| Cockroach | 107 | 0 (0-8) | 29 | 107 | 0 (0-0) | 20 |
| HDM | 107 | 0 (0-90) | 59 | 107 | 35 (0-172) | 61 |
| IL-5 | ||||||
| Medium | 107 | 0 (0-0) | 18*** | 92 | 0 (0-0) | 2 |
| SEB | 107 | 1,374 (850-1,902)*** | 100 | 92 | 1,992 (1,274-1,992) | 100 |
| Ascaris | 107 | 11 (0-69)* | 60 | 92 | 43 (0-173) | 74 |
| PPD | 107 | 4 (0-33) | 56 | 92 | 3 (0-38) | 55 |
| LPS | 107 | 0 (0-0) | 15 | 92 | 0 (0-0) | 5 |
| Cockroach | 107 | 0 (0-0) | 16 | 92 | 0 (0-0) | 12 |
| HDM | 107 | 0 (0-0) | 8 | 92 | 0 (0-0) | 5 |
| IL-13 | ||||||
| Medium | 104 | 0 (0-0) | 22 | 106 | 0 (0-8) | 30 |
| SEB | 104 | 4,274 (2,929-6,991)* | 100 | 106 | 5,919 (3,651-7,440) | 100 |
| Ascaris | 104 | 18 (0-141)* | 65 | 106 | 84 (0-1279) | 75 |
| PPD | 104 | 10 (0-124) | 59 | 106 | 10 (0-92) | 58 |
| LPS | 104 | 0 (0-2) | 28 | 106 | 0 (0-3) | 28 |
| Cockroach | 104 | 0 (0-1) | 26 | 106 | 0 (0-2) | 30 |
| HDM | 104 | 0 (0-0) | 23 | 106 | 0 (0-4) | 35 |
| Histamine release | ||||||
| Ascaris antigen | ||||||
| Ascaris adult | 32 | 39 (3-69) | 69 | 19 | 47 (9-94) | 74 |
| Larval L2/L3 | 32 | 28 (1-100) | 94 | 19 | 75 (42-108) | 84 |
| Larval L3/L4 | 32 | 95 (62-100) | 91 | 19 | 100 (71-100) | 89 |
| Aeroallergen | ||||||
| D.pteronyssinus | 32 | 1 (0-3) | 15 | 19 | 0 (0-2) | 6 |
| Der p1 | 32 | 0 (0-2) | 7 | 19 | 0 (0-6) | 11 |
| Der p2 | 32 | 0 (0-3) | 3 | 19 | 0 (0-1) | 0 |
| P.americana | 32 | 3 (1-10) | 27 | 19 | 2 (2-8) | 17 |
Cytokine levels and histamine release among the children that either received albendazole treatments (107 children) or no treatment (107 children) at the end of the 12-month observation period. Sample sizes (N) for cytokine and histamine release assays are shown. IQR-interquartile range. R (%) - proportion of individuals with detectable cytokine levels or with >10% histamine release. P values are from bivariate analyses:
*
- P≤0.01
**
- P≤0.001
***
- P≤0.0001.